United States Shock Wave Therapy Devices Market Size, Share - Growth Analysis Report and Forecast Trends (2026-2035)

The United States shock wave therapy devices market was valued at USD 5.57 Million in 2025, driven by the advancement of shock wave therapy technologies in the region. The market is anticipated to grow at a CAGR of 5.10% during the forecast period of 2026-2035, with the values likely to reach USD 9.16 Million by 2035. The market is driven by increasing demand for non-invasive treatments and the aging population's growing need for musculoskeletal pain management in the forecast period.

Q1 2026 Market Updates

The Iran-US-Israel conflict that escalated on February 28, 2026, is introducing supply chain and cost pressures for the United States shock wave therapy devices market, which generated USD 68 million in 2024 and is projected to grow at a CAGR of 4.3% through 2034. The Strait of Hormuz closure and disruption of Gulf logistics corridors have impacted global medical device supply chains, with semiconductor-grade helium supply reduced by approximately one-third following the Iranian drone attack on Qatar's Ras Laffan facility. Shock wave therapy devices rely on specialized electronic components and precision-manufactured parts that are affected by the broader semiconductor and materials supply tightening.

The conflict has driven global oil prices up approximately 45% since late February, increasing manufacturing and transportation costs for medical device companies. Shock wave therapy equipment - including both radial and focused devices used in orthopedic, urological, and rehabilitation applications - contains components sourced from international supply chains now facing disruption. The radial technique segment, which dominated the market with 48.3% revenue share in 2025, relies on devices with piezoelectric and electromagnetic generators that require specialized materials increasingly affected by supply constraints.

Hospitals, which hold 41.6% of the market share and represent the primary end-user segment, face budget pressures as healthcare costs rise across the board due to the conflict's impact on pharmaceutical and device pricing. The US healthcare system is simultaneously managing broader supply chain disruptions for medicines and equipment, which could shift institutional capital allocation priorities and potentially delay procurement of non-emergency devices like shock wave therapy systems. However, the growing preference for non-invasive treatments over surgical alternatives continues to support demand.

The shock wave therapy market's growth trajectory remains supported by rising musculoskeletal disorder prevalence and expanding clinical applications, including wound healing and erectile dysfunction treatment. Near-term headwinds from elevated manufacturing costs and supply chain delays may slow device upgrades and new installations, but the underlying clinical demand remains robust as practitioners increasingly adopt shock wave therapy as a first-line non-surgical intervention.

Key Takeaways

Government: US regulatory bodies should monitor medical device supply chain disruptions and consider expedited approval pathways for alternative component suppliers to maintain device availability. Supporting domestic manufacturing of specialized medical device components can reduce vulnerability to the geopolitical supply chain disruptions affecting the broader healthcare equipment sector.

Market: The US shock wave therapy devices market faces near-term cost pressures from rising material and logistics expenses driven by the Middle East conflict. Device manufacturers should optimize supply chains and consider strategic inventory building to maintain competitive pricing while the conflict drives up semiconductor and specialized component costs across the medical device industry.

Procurement: Healthcare procurement teams should accelerate purchasing timelines for shock wave therapy equipment ahead of anticipated price increases. Securing service and maintenance contracts at current rates and building component spare parts inventory will help manage costs as the conflict-driven supply chain disruptions continue to affect medical device availability and pricing.